Browse the corpus

1 INDICATIONS AND USAGE Calcipotriene foam is indicated for the topical treatment of plaque psoriasis of the scalp and body in adults and pediatric patients 4 years of age and older. Calcipotriene foam, is a vitamin D analog indicated for the topical treatment of plaque psoriasis of the scalp and body in adults and pediatric patients 4 years of age and older. ( 1 )

2 DOSAGE AND ADMINISTRATION Calcipotriene foam is for topical use only. Calcipotriene foam is not for oral, ophthalmic, or intravaginal use. Apply a thin layer of calcipotriene foam twice daily to the affected areas and rub in gently and completely. Avoid contact with the face and eyes. For topical use only; not for oral, ophthalmic, or intravaginal use. ( 2 ) Apply twice daily. ( 2 )

5 WARNINGS AND PRECAUTIONS Flammability: Contents are flammable. Instruct the patient the avoid fire, flame, and smoking during and immediately following application. ( 5.1 ) Effects on Calcium Metabolism: If elevation of serum calcium occurs, instruct patients to discontinue treatment until normal calcium levels are restored. ( 5.2 ) 5.1 Flammability The propellant in calcipotriene foam is flammable. Instruct the patient to avoid fire, flame, and smoking during and immediately following application. 5.2 Effects on Calcium Metabolism Elevation of serum calcium has occurred with use of calcipotriene. If elevation in serum calcium outside the normal range should occur, discontinue treatment until normal calcium levels are restored.

6 ADVERSE REACTIONS Adverse reactions reported in ≥ 1% of subjects treated with Calcipotriene foam and at a higher incidence than subjects treated with vehicle were application site erythema and application site pain. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Mayne Pharma at 1-844-825-8500 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . ( 6 ) 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice. Calcipotriene foam was studied in four vehicle-controlled trials. A total of 1094 adult subjects with plaque psoriasis, including 654 exposed to calcipotriene foam, were treated twice daily for 8 weeks. Adverse reactions reported in ≥1% of subjects treated with calcipotriene foam and at a higher incidence than subjects treated with vehicle were application site erythema (2%) and application site pain (3%). The incidence of these adverse reactions was similar between the body and scalp. In an open-label study, 19 pediatric subjects age 12 to less than 17 years applied calcipotriene foam twice daily for 14 days and once on Day 15. Adverse reactions included application site pain, application site pruritus and pruritus [see Clinical Pharmacology (12.2 and 12.3) and Pediatric Use (8.4) ] . In an open-label study, 36 pediatric subjects age 4 to less than 12 years applied calcipotriene foam twice daily for up to 8 weeks. Adverse reactions included application site pain and contact dermatitis [see Clinical Pharmacology (12.2 and 12.3) and Pediatric Use (8.4) ] . 6.2 Postmarketing Experience The following adverse reactions have been identified during post approval use of calcipotriene foam. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Skin and Subcutaneous: application site vesicles

8 USE IN SPECIFIC POPULATIONS 8.1 Pregnancy Risk Summary Although there are no available data on the drug- associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes in pregnant women exposed to calcipotriene foam, systemic exposure to calcipotriene is likely to be low [see Clinical Pharmacology (12.2 , 12.3) ] . In animal reproduction studies, oral administration of calcipotriene to pregnant rats and rabbits during the period of organogenesis resulted in an increased incidence of minor skeletal abnormalities, including enlarged fontanelles and extra ribs in rats and an increased incidence of minor skeletal abnormalities, including incomplete ossification of pubic bones and forelimb phalanges in rabbits (see Data ) . The available data do not allow the calculation of relevant comparisons between the systemic exposure of calcipotriene observed in animal studies to the systemic exposure that would be expected in humans after topical use of calcipotriene foam. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. Data Animal Data Embryofetal development studies were conducted with calcipotriene after oral administration in rats and rabbits. Pregnant rats received daily oral administration of calcipotriene during the period of organogenesis. Fetuses from dams dosed with 54 mcg/kg/day (318 mcg/m 2 /day) exhibited a significantly increased incidence of minor skeletal abnormalities consisting primarily of enlarged fontanelles and extra ribs. The enlarged fontanelles are most likely due to calcipotriene's effect upon calcium metabolism. There were no effects on the incidence of major malformations in fetuses. Pregnant rabbits received daily oral administration of calcipotriene during the period of organogenesis. Increased rabbit maternal and fetal toxicity was noted at 12 mcg/kg/day (132 mcg/m 2 /day). Fetuses from does dosed with 36 mcg/kg/day (396 mcg/m 2 /day) exhibited a significantly increased incidence of minor skeletal abnormalities including incomplete ossification of pubic bones and forelimb phalanges. There were no effects on the incidence of major malformations in fetuses. 8.2 Lactation Risk Summary There are no data on the presence of topically administered calcipotriene in human or animal milk, the effects on the breastfed infant, or the effects on milk production. After topical administration of calcipotriene foam, concentrations of calcipotriene in plasma are low, and therefore, concentrations in human milk are likely to be low [see Clinical Pharmacology (12.3) ] . The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for and any potential adverse effects on the breastfed child from calcipotriene foam or from the underlying maternal condition. 8.4 Pediatric Use The safety and effectiveness of calcipotriene foam have been established in pediatric patients age 4 years and older for topical treatment of plaque psoriasis of the scalp and body.

any potential adverse effects on the breastfed child from calcipotriene foam or from the underlying maternal condition. 8.4 Pediatric Use The safety and effectiveness of calcipotriene foam have been established in pediatric patients age 4 years and older for topical treatment of plaque psoriasis of the scalp and body. Use of calcipotriene foam in this age group is supported by two adequate and well controlled 8-week trials in adults and adolescents 12 years of age and older, with additional data from a 15-day open-label safety and pharmacokinetics (PK) study conducted in 19 subjects 12 to less than 17 years of age; and an 8-week open-label safety and PK study in 36 subjects 4 to 11 years of age with psoriasis. Data from 19 subjects aged 12 to less than 17 years and 18 subjects aged 5 to 11 years showed no significant effects on indices of calcium metabolism. Systemic concentrations of calcipotriene were not quantifiable in the two studies in subjects aged 7 years to less than 17 years. [see Clinical Studies (14) , Clinical Pharmacology (12.2 , 12.3) and Adverse Reactions (6.1) ] . The safety and effectiveness of calcipotriene foam in pediatric patients less than 4 years of age have not been established. 8.5 Geriatric Use Clinical trials of calcipotriene foam did not include sufficient numbers of subjects aged 65 years and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients.

8.1 Pregnancy Risk Summary Although there are no available data on the drug- associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes in pregnant women exposed to calcipotriene foam, systemic exposure to calcipotriene is likely to be low [see Clinical Pharmacology (12.2 , 12.3) ] . In animal reproduction studies, oral administration of calcipotriene to pregnant rats and rabbits during the period of organogenesis resulted in an increased incidence of minor skeletal abnormalities, including enlarged fontanelles and extra ribs in rats and an increased incidence of minor skeletal abnormalities, including incomplete ossification of pubic bones and forelimb phalanges in rabbits (see Data ) . The available data do not allow the calculation of relevant comparisons between the systemic exposure of calcipotriene observed in animal studies to the systemic exposure that would be expected in humans after topical use of calcipotriene foam. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. Data Animal Data Embryofetal development studies were conducted with calcipotriene after oral administration in rats and rabbits. Pregnant rats received daily oral administration of calcipotriene during the period of organogenesis. Fetuses from dams dosed with 54 mcg/kg/day (318 mcg/m 2 /day) exhibited a significantly increased incidence of minor skeletal abnormalities consisting primarily of enlarged fontanelles and extra ribs. The enlarged fontanelles are most likely due to calcipotriene's effect upon calcium metabolism. There were no effects on the incidence of major malformations in fetuses. Pregnant rabbits received daily oral administration of calcipotriene during the period of organogenesis. Increased rabbit maternal and fetal toxicity was noted at 12 mcg/kg/day (132 mcg/m 2 /day). Fetuses from does dosed with 36 mcg/kg/day (396 mcg/m 2 /day) exhibited a significantly increased incidence of minor skeletal abnormalities including incomplete ossification of pubic bones and forelimb phalanges. There were no effects on the incidence of major malformations in fetuses.

8.4 Pediatric Use The safety and effectiveness of calcipotriene foam have been established in pediatric patients age 4 years and older for topical treatment of plaque psoriasis of the scalp and body. Use of calcipotriene foam in this age group is supported by two adequate and well controlled 8-week trials in adults and adolescents 12 years of age and older, with additional data from a 15-day open-label safety and pharmacokinetics (PK) study conducted in 19 subjects 12 to less than 17 years of age; and an 8-week open-label safety and PK study in 36 subjects 4 to 11 years of age with psoriasis. Data from 19 subjects aged 12 to less than 17 years and 18 subjects aged 5 to 11 years showed no significant effects on indices of calcium metabolism. Systemic concentrations of calcipotriene were not quantifiable in the two studies in subjects aged 7 years to less than 17 years. [see Clinical Studies (14) , Clinical Pharmacology (12.2 , 12.3) and Adverse Reactions (6.1) ] . The safety and effectiveness of calcipotriene foam in pediatric patients less than 4 years of age have not been established.

8.5 Geriatric Use Clinical trials of calcipotriene foam did not include sufficient numbers of subjects aged 65 years and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients.

10 OVERDOSAGE Topically applied calcipotriene can be absorbed in sufficient amounts to produce systemic effects. Elevated serum calcium has been observed with use of topical calcipotriene [See Warnings and Precautions (5.2) ] .

11 DESCRIPTION Calcipotriene foam contains the compound calcipotriene, a synthetic vitamin D3 analog, in an aqueous-based emulsion foam vehicle for topical dermatologic use. Chemically, calcipotriene is (5Z,7E,22E,24S)-24-cyclopropyl-9,10-secochola-5,7,10(19), 22-tetraene- 1α,3β,24-triol. The structural formula is represented below: Molecular Formula: C27H40O3 Molecular Weight: 412.6 Calcipotriene is a white or off-white crystalline substance. Calcipotriene foam contains calcipotriene 50 mcg/g in an aqueous-based emulsion foam vehicle consisting of cetyl alcohol, dibasic sodium phosphate, dl-α-tocopherol, edetate disodium, isopropyl myristate, light mineral oil, polyoxyl 20 cetostearyl ether, propylene glycol, purified water, stearyl alcohol, and white petrolatum. Calcipotriene foam is dispensed from an aluminum can pressurized with a hydrocarbon (propane/n-butane/isobutane) propellant. Chemical Structure

12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Calcipotriene is a synthetic vitamin D3 analog that has a similar receptor binding affinity as natural vitamin D3. However, the exact mechanism of action contributing to the clinical efficacy in the treatment of psoriasis is unknown. 12.2 Pharmacodynamics Effects on Calcium Metabolism In 19 subjects with psoriasis aged 12 to less than 17 years treated with calcipotriene foam two times a day for 15 days, there was no significant effect on indices of calcium metabolism including serum albumin adjusted calcium, urine calcium/creatinine ratio, iPTH, alkaline phosphatase, magnesium and phosphorus. The effects of calcipotriene foam, 0.005%, on calcium metabolism were evaluated in 18 pediatric subjects 5 to 11 years of age receiving calcipotriene foam administered twice daily for a minimum of 14 days (mean: 56 days, range: 14 to 69 days). These subjects had plaque psoriasis involving an average of 10% of the body surface area (BSA) (range: 0.5%-36.5%). There was no relationship between urinary calcium/creatinine ratio (comparing Week 2 to Baseline) and % BSA treated. 12.3 Pharmacokinetics The systemic absorption of calcipotriene in subjects with psoriasis of the body was evaluated at steady state following application of either calcipotriene foam or calcipotriene ointment to a body surface area of 5% to 10%. In the calcipotriene foam treatment group, 15 out of 16 subjects had calcipotriene plasma concentrations below the limit of quantitation (10 pg/mL), while in the calcipotriene ointment treated group, 5 out of 16 subjects had measurable calcipotriene plasma concentrations at various time points. All measurable plasma calcipotriene concentrations were below 25 pg/mL. The pharmacokinetics of calcipotriene foam, 0.005% was investigated when applied topically for 15 days to 17 subjects aged 12 to less than 17 years with moderate plaque psoriasis involving a mean BSA of 24%, excluding face and scalp, and a mean scalp involvement of 43%. Systemic concentration of calcipotriene were not quantifiable in any of the subjects (limit of quantification = 10 pg/mL). In 11 pediatric subjects 7 to 11 years of age with plaque psoriasis involving a mean BSA of 10%, plasma concentration of calcipotriene was measured following 2 weeks of twice daily administration of calcipotriene foam. No subject had quantifiable calcipotriene plasma concentration (limit of quantification = 10 pg/mL). The systemic disposition of calcipotriene is expected to be similar to that of the naturally occurring vitamin D. Absorbed calcipotriene is known to be converted to inactive metabolites within 24 hours of application and the metabolism occurs via a similar pathway to the natural hormone.

12.1 Mechanism of Action Calcipotriene is a synthetic vitamin D3 analog that has a similar receptor binding affinity as natural vitamin D3. However, the exact mechanism of action contributing to the clinical efficacy in the treatment of psoriasis is unknown.

12.2 Pharmacodynamics Effects on Calcium Metabolism In 19 subjects with psoriasis aged 12 to less than 17 years treated with calcipotriene foam two times a day for 15 days, there was no significant effect on indices of calcium metabolism including serum albumin adjusted calcium, urine calcium/creatinine ratio, iPTH, alkaline phosphatase, magnesium and phosphorus. The effects of calcipotriene foam, 0.005%, on calcium metabolism were evaluated in 18 pediatric subjects 5 to 11 years of age receiving calcipotriene foam administered twice daily for a minimum of 14 days (mean: 56 days, range: 14 to 69 days). These subjects had plaque psoriasis involving an average of 10% of the body surface area (BSA) (range: 0.5%-36.5%). There was no relationship between urinary calcium/creatinine ratio (comparing Week 2 to Baseline) and % BSA treated.

12.3 Pharmacokinetics The systemic absorption of calcipotriene in subjects with psoriasis of the body was evaluated at steady state following application of either calcipotriene foam or calcipotriene ointment to a body surface area of 5% to 10%. In the calcipotriene foam treatment group, 15 out of 16 subjects had calcipotriene plasma concentrations below the limit of quantitation (10 pg/mL), while in the calcipotriene ointment treated group, 5 out of 16 subjects had measurable calcipotriene plasma concentrations at various time points. All measurable plasma calcipotriene concentrations were below 25 pg/mL. The pharmacokinetics of calcipotriene foam, 0.005% was investigated when applied topically for 15 days to 17 subjects aged 12 to less than 17 years with moderate plaque psoriasis involving a mean BSA of 24%, excluding face and scalp, and a mean scalp involvement of 43%. Systemic concentration of calcipotriene were not quantifiable in any of the subjects (limit of quantification = 10 pg/mL). In 11 pediatric subjects 7 to 11 years of age with plaque psoriasis involving a mean BSA of 10%, plasma concentration of calcipotriene was measured following 2 weeks of twice daily administration of calcipotriene foam. No subject had quantifiable calcipotriene plasma concentration (limit of quantification = 10 pg/mL). The systemic disposition of calcipotriene is expected to be similar to that of the naturally occurring vitamin D. Absorbed calcipotriene is known to be converted to inactive metabolites within 24 hours of application and the metabolism occurs via a similar pathway to the natural hormone.

13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Calcipotriene topically administered to mice for up to 24 months at dose levels of 3, 10, or 30 mcg/kg/day (corresponding to 9, 30, or 90 mcg /m 2 /day) showed no significant changes in tumor incidence when compared with controls. The genotoxic potential of calcipotriene was evaluated in an Ames assay, a mouse lymphoma TK locus assay, a human lymphocyte chromosome aberration assay, and a mouse micronucleus assay. All assay results were negative. Studies in rats at oral doses up to 54 mcg /kg/day (318 mcg /m 2 /day) of calcipotriene indicated no impairment of fertility or general reproductive performance.

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Calcipotriene topically administered to mice for up to 24 months at dose levels of 3, 10, or 30 mcg/kg/day (corresponding to 9, 30, or 90 mcg /m 2 /day) showed no significant changes in tumor incidence when compared with controls. The genotoxic potential of calcipotriene was evaluated in an Ames assay, a mouse lymphoma TK locus assay, a human lymphocyte chromosome aberration assay, and a mouse micronucleus assay. All assay results were negative. Studies in rats at oral doses up to 54 mcg /kg/day (318 mcg /m 2 /day) of calcipotriene indicated no impairment of fertility or general reproductive performance.

14 CLINICAL STUDIES In two multi-center, randomized, double-blind, vehicle-controlled clinical trials a total of 659 subjects with psoriasis were randomized 2:1 to calcipotriene foam or vehicle; subjects applied the assigned treatment twice daily for 8 weeks. Baseline disease severity was graded using a 5-point Investigator Static Global Assessment scale (ISGA), on which subjects scored either "mild" or "moderate" as shown in Table 1. Table 1. Investigator Static Global Assessment (ISGA) Scale for Body Disease Severity Grade Definition Clear 0 No evidence of scaling, erythema, or plaque thickness Almost clear 1 Occasional fine scale, faint erythema, and barely perceptible plaque thickness Mild 2 Fine scale with light coloration and mild plaque elevation Moderate 3 Coarse scale with moderate red coloration and moderate plaque thickness Severe 4 Thick tenacious scale with deep coloration and severe plaque thickness Efficacy evaluation was carried out at Week 8 with treatment success being defined as a score of "clear" (grade 0) or "almost clear" (grade 1) and at least 2 grade improvement from the baseline score. Approximately 30% of enrolled subjects were graded as "mild" on the ISGA scale. The study population ranged in age from 12 to 89 years with 10 subjects less than 18 years of age at baseline. The subjects were 54% male and 88% Caucasian. Table 2 presents the efficacy results for each trial. Table 2. Number and Percent of Subjects Achieving Success for Body at Week 8 in Each Trial Trial 1 Trial 2 Calcipotriene Foam N = 223 Vehicle Foam N = 113 Calcipotriene Foam N = 214 Vehicle Foam N = 109 Number (%) of Subjects with Treatment Success 31 (14%) 8 (7%) 58 (27%) 17 (16%) In one trial, subjects graded as "mild" at baseline showed a greater response to vehicle than calcipotriene foam. Table 3 presents the success rates by disease severity at baseline for each trial. Table 3. Number and Percent of Subjects Achieving Success for Body by Baseline ISGA Score and by Trial ISGA Scores at Baseline Trial 1 Trial 2 Calcipotriene Foam (N = 223) Vehicle Foam (N = 113) Calcipotriene Foam (N = 214) Vehicle Foam (N = 109) Mild 2/73 (2.7%) 3/34 (8.8%) 8/56 (14.3%) 4/31 (12.9%) Moderate 29/150 (19.3%) 5/79 (6.3%) 50/158 (31.6%) 13/78 (16.7%) In another multi-center, randomized, double-blind, vehicle-controlled clinical trial, a total of 363 subjects with moderate plaque psoriasis of the scalp and body were randomized 1:1 to calcipotriene foam or vehicle. Subjects applied the assigned treatment to the affected areas twice daily for 8 weeks. Baseline disease severity of the scalp was graded using a 6-point ISGA; a score of "moderate" corresponded to grade 3. The primary efficacy evaluation for scalp involvement was carried out at Week 8 with treatment success being defined as a score of "clear" (grade 0) or "almost clear" (grade 1). The study population ranged in age from 12 to 97 years with 11 subjects less than 18 years of age at baseline. The subjects were 60% male and 87% Caucasian. Table 4 presents the efficacy results for the trial. Table 4. Number and Percent of Subjects Achieving Success for Scalp at Week 8 Trial 3 Calcipotriene Foam Vehicle Foam N = 181 N = 182 Number (%) of Subjects with Treatment Success 74 (41%) 44 (24%) The contribution to efficacy of individual components of the vehicle has not been established.

<table width="80%"><caption>Table 1. Investigator Static Global Assessment (ISGA) Scale for Body</caption><col width="25%" align="left" valign="top"/><col width="15%" align="center" valign="top"/><col width="60%" align="left" valign="top"/><thead><tr><th styleCode="Lrule Rrule">Disease Severity</th><th styleCode="Rrule" align="left">Grade</th><th styleCode="Rrule">Definition</th></tr></thead><tbody><tr styleCode="Botrule"><td styleCode="Lrule Rrule">Clear</td><td styleCode="Rrule">0</td><td styleCode="Rrule">No evidence of scaling, erythema, or plaque thickness</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule">Almost clear</td><td styleCode="Rrule">1</td><td styleCode="Rrule">Occasional fine scale, faint erythema, and barely perceptible plaque thickness</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule">Mild</td><td styleCode="Rrule">2</td><td styleCode="Rrule">Fine scale with light coloration and mild plaque elevation</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule">Moderate</td><td styleCode="Rrule">3</td><td styleCode="Rrule">Coarse scale with moderate red coloration and moderate plaque thickness</td></tr><tr><td styleCode="Lrule Rrule">Severe</td><td styleCode="Rrule">4</td><td styleCode="Rrule">Thick tenacious scale with deep coloration and severe plaque thickness</td></tr></tbody></table> <table width="80%"><caption>Table 2. Number and Percent of Subjects Achieving Success for Body at Week 8 in Each Trial</caption><col width="36%" align="left" valign="top"/><col width="16%" align="center" valign="top"/><col width="16%" align="center" valign="top"/><col width="16%" align="center" valign="top"/><col width="16%" align="center" valign="top"/><thead><tr><th styleCode="Lrule Rrule" rowspan="2"/><th styleCode="Rrule Botrule" colspan="2">Trial 1</th><th styleCode="Rrule Botrule" colspan="2">Trial 2</th></tr><tr><th styleCode="Rrule" align="center">Calcipotriene Foam N = 223</th><th styleCode="Rrule">Vehicle Foam N = 113</th><th styleCode="Rrule">Calcipotriene Foam N = 214</th><th styleCode="Rrule">Vehicle Foam N = 109</th></tr></thead><tbody><tr><td styleCode="Lrule Rrule">Number (%) of Subjects with Treatment Success</td><td styleCode="Rrule">31 (14%)</td><td styleCode="Rrule">8 (7%)</td><td styleCode="Rrule">58 (27%)</td><td styleCode="Rrule">17 (16%)</td></tr></tbody></table>

N = 214</th><th styleCode="Rrule">Vehicle Foam N = 109</th></tr></thead><tbody><tr><td styleCode="Lrule Rrule">Number (%) of Subjects with Treatment Success</td><td styleCode="Rrule">31 (14%)</td><td styleCode="Rrule">8 (7%)</td><td styleCode="Rrule">58 (27%)</td><td styleCode="Rrule">17 (16%)</td></tr></tbody></table> <table width="80%"><caption>Table 3. Number and Percent of Subjects Achieving Success for Body by Baseline ISGA Score and by Trial</caption><col width="36%" align="center" valign="top"/><col width="17%" align="center" valign="top"/><col width="15%" align="center" valign="top"/><col width="17%" align="center" valign="top"/><col width="15%" align="center" valign="top"/><thead><tr><th styleCode="Lrule Rrule" rowspan="2" valign="bottom" align="left">ISGA Scores at Baseline</th><th styleCode="Rrule Botrule" colspan="2">Trial 1</th><th styleCode="Rrule Botrule" colspan="2">Trial 2</th></tr><tr><th styleCode="Rrule">Calcipotriene Foam (N = 223)</th><th styleCode="Rrule">Vehicle Foam (N = 113)</th><th styleCode="Rrule">Calcipotriene Foam (N = 214)</th><th styleCode="Rrule">Vehicle Foam (N = 109)</th></tr></thead><tbody><tr styleCode="Botrule"><td styleCode="Lrule Rrule">Mild</td><td styleCode="Rrule">2/73 (2.7%)</td><td styleCode="Rrule">3/34 (8.8%)</td><td styleCode="Rrule">8/56 (14.3%)</td><td styleCode="Rrule">4/31 (12.9%)</td></tr><tr><td styleCode="Lrule Rrule">Moderate</td><td styleCode="Rrule">29/150 (19.3%)</td><td styleCode="Rrule">5/79 (6.3%)</td><td styleCode="Rrule">50/158 (31.6%)</td><td styleCode="Rrule">13/78 (16.7%)</td></tr></tbody></table> <table width="80%"><caption>Table 4. Number and Percent of Subjects Achieving Success for Scalp at Week 8</caption><col width="60%" align="left" valign="top"/><col width="25%" align="center" valign="top"/><col width="15%" align="center" valign="top"/><thead><tr><th styleCode="Lrule Rrule" rowspan="3"/><th styleCode="Rrule Botrule" colspan="2">Trial 3</th></tr><tr><th styleCode="Rrule" align="center">Calcipotriene Foam</th><th styleCode="Rrule">Vehicle Foam</th></tr><tr><th styleCode="Rrule" align="center">N = 181</th><th styleCode="Rrule">N = 182</th></tr></thead><tbody><tr><td styleCode="Lrule Rrule">Number (%) of Subjects with Treatment Success</td><td styleCode="Rrule">74 (41%)</td><td styleCode="Rrule">44 (24%)</td></tr></tbody></table>

16 HOW SUPPLIED/STORAGE AND HANDLING 16.1 How Supplied Calcipotriene foam, 0.005%, is supplied as follows: 60 g aluminum can NDC 51862-512-60 16.2 Storage and Handling Store at 20ºC to 25°C (68°F to 77°F); excursions permitted to 15°C – 30°C (59°F – 86°F). Flammable. Contents under pressure. Do not puncture or incinerate. Do not expose to heat or store at temperatures above 120°F (49°C). Keep out of reach of children.

<table width="35%" styleCode="Noautorules"><col width="50%" align="left" valign="top"/><col width="50%" align="left" valign="top"/><tbody><tr><td>60 g aluminum can</td><td>NDC 51862-512-60</td></tr></tbody></table>

16.2 Storage and Handling Store at 20ºC to 25°C (68°F to 77°F); excursions permitted to 15°C – 30°C (59°F – 86°F). Flammable. Contents under pressure. Do not puncture or incinerate. Do not expose to heat or store at temperatures above 120°F (49°C). Keep out of reach of children.

17 PATIENT COUNSELING INFORMATION Advise the patient to read the FDA-approved patient labeling (Patient Information). Inform the patient to adhere to the following instructions: Apply calcipotriene foam to the affected skin areas. Apply calcipotriene foam to the scalp when the hair is dry. Avoid fire, flame, and smoking during and immediately following application since calcipotriene foam is flammable. Avoid contact with the face and eyes. If calcipotriene foam gets on the face or in or near their eyes, rinse thoroughly with water. Talk to your doctor if your skin does not improve after treatment with calcipotriene foam for 8 weeks. Wash your hands after applying calcipotriene foam unless your hands are the affected site. Do not place calcipotriene foam in the refrigerator or freezer.

Patient Information Calcipotriene (KAL-si-poe-TYRE-een)Foam, 0.005% This Patient Information has been approved by the U.S. Food and Drug Administration. Revised: 04/2024 Important: Calcipotriene Foam is for use on the skin only (topical use). Do not use calcipotriene foam in your mouth, eyes, or vagina. WHAT IS CALCIPOTRIENE FOAM? Calcipotriene foam is a prescription medicine used on the skin (topical) to treat plaque psoriasis of the scalp and body in people 4 years of age and older. It is not known if calcipotriene foam is safe and effective in people under 4 years old. Do not use Calcipotriene Foam if you have been told by your healthcare provider that you have a high level of calcium in your blood (hypercalcemia). BEFORE USING CALCIPOTRIENE FOAM, TELL YOUR HEALTHCARE PROVIDER ABOUT ALL YOUR MEDICAL CONDITIONS, INCLUDING IF YOU: are pregnant or planning to become pregnant. It is not known if calcipotriene foam will harm your unborn baby. are breastfeeding or plan to breastfeed. It is not known if calcipotriene foam passes into your breast milk. Talk to your healthcare provider about the best way to feed your baby during treatment with calcipotriene foam. Tell your healthcare provider about all the medicines you take , including prescription and over-the-counter medicines, vitamins, and herbal supplements. Know the medicines you take. Keep a list of your medicines with you to show your healthcare provider and pharmacist when you get a new medicine. HOW SHOULD I USE CALCIPOTRIENE FOAM? Use calcipotriene foam exactly as your healthcare provider tells you to use it. See the detailed " Instructions for Use " at the end of this leaflet for directions about how to apply calcipotriene foam the right way. Calcipotriene foam is usually applied to the affected skin areas 2 times each day. For your scalp, apply calcipotriene foam when your hair is dry. Talk with your healthcare provider if your skin does not improve after 8 weeks of treatment with calcipotriene foam. Wash your hands after applying calcipotriene foam unless you are using the medicine to treat your hands. WHAT SHOULD I AVOID WHILE USING CALCIPOTRIENE FOAM? Calcipotriene foam is flammable . Avoid fire, flame, and smoking during and right after you apply calcipotriene foam. Avoid getting calcipotriene foam on your face or in or near your eyes. If calcipotriene foam gets on your face or in your eyes, rinse well with water. WHAT ARE THE POSSIBLE SIDE EFFECTS OF CALCIPOTRIENE FOAM? Calcipotriene foam may cause serious side effects, including: Too much calcium in your blood. Your healthcare provider may tell you to stop using calcipotriene foam until your calcium levels become normal. The most common side effects of Calcipotriene foam include redness and pain of the treated skin areas. These are not all the possible side effects of calcipotriene foam. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. You may also report side effects to Mayne Pharma at 1-844-825-8500. HOW SHOULD I STORE CALCIPOTRIENE FOAM? Store calcipotriene foam at room temperature, between 68°F to 77°F (20C° to 25°C). Do not store calcipotriene foam in the refrigerator or freezer. Do not expose calcipotriene foam to heat or store at temperatures above 120°F (49°C). Do not puncture or burn the calcipotriene foam can. Keep calcipotriene foam and all medicines out of the reach of children.

perature, between 68°F to 77°F (20C° to 25°C). Do not store calcipotriene foam in the refrigerator or freezer. Do not expose calcipotriene foam to heat or store at temperatures above 120°F (49°C). Do not puncture or burn the calcipotriene foam can. Keep calcipotriene foam and all medicines out of the reach of children. GENERAL INFORMATION ABOUT THE SAFE AND EFFECTIVE USE OF CALCIPOTRIENE FOAM. Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use calcipotriene foam for a condition for which it was not prescribed. Do not give calcipotriene foam to other people even if they have the same symptoms you have. It may harm them. You can ask your healthcare provider or pharmacist for information about calcipotriene foam that is written for health professionals. WHAT ARE THE INGREDIENTS IN CALCIPOTRIENE FOAM? Active ingredient: calcipotriene Inactive ingredients: cetyl alcohol, dibasic sodium phosphate, dl-α-tocopherol, edetate disodium, isopropyl myristate, light mineral oil, polyoxyl 20 cetostearyl ether, propylene glycol, purified water, stearyl alcohol, and white petrolatum. The foam is dispensed from an aluminum can pressurized with a hydrocarbon (propane/n-butane/isobutane) propellant. Distributed by: Mayne Pharma Raleigh, NC 27609

<table width="`100%"><col width="80%" align="left" valign="top"/><col width="20%" align="right" valign="top"/><thead><tr><th styleCode="Lrule Rrule" colspan="2" align="center">Patient Information Calcipotriene (KAL-si-poe-TYRE-een)Foam, 0.005%</th></tr></thead><tfoot><tr><td align="left" colspan="1">This Patient Information has been approved by the U.S. Food and Drug Administration. </td><td align="left" colspan="1">Revised: 04/2024</td></tr></tfoot><tbody><tr styleCode="Botrule"><td styleCode="Lrule Rrule" colspan="2"><content styleCode="bold">Important: Calcipotriene Foam is for use on the skin only (topical use).</content> Do not use calcipotriene foam in your mouth, eyes, or vagina.</td></tr><tr><td styleCode="Lrule Rrule" colspan="2"><content styleCode="bold">WHAT IS CALCIPOTRIENE FOAM?</content></td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule" colspan="2">Calcipotriene foam is a prescription medicine used on the skin (topical) to treat plaque psoriasis of the scalp and body in people 4 years of age and older. It is not known if calcipotriene foam is safe and effective in people under 4 years old.</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule" colspan="2"><content styleCode="bold">Do not use Calcipotriene Foam if</content> you have been told by your healthcare provider that you have a high level of calcium in your blood (hypercalcemia).</td></tr><tr><td styleCode="Lrule Rrule" colspan="2"><content styleCode="bold">BEFORE USING CALCIPOTRIENE FOAM, TELL YOUR HEALTHCARE PROVIDER ABOUT ALL YOUR MEDICAL CONDITIONS, INCLUDING IF YOU:</content></td></tr><tr><td styleCode="Lrule Rrule" colspan="2"><list listType="unordered" styleCode="Disc"><item>are pregnant or planning to become pregnant. It is not known if calcipotriene foam will harm your unborn baby.</item><item>are breastfeeding or plan to breastfeed. It is not known if calcipotriene foam passes into your breast milk. Talk to your healthcare provider about the best way to feed your baby during treatment with calcipotriene foam.</item></list></td></tr><tr><td styleCode="Lrule Rrule" colspan="2"><content styleCode="bold">Tell your healthcare provider about all the medicines you take</content>, including prescription and over-the-counter medicines, vitamins, and herbal supplements.</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule" colspan="2">Know the medicines you take. Keep a list of your medicines with you to show your healthcare provider and pharmacist when you get a new medicine.</td></tr><tr><td styleCode="Lrule Rrule" colspan="2"><content styleCode="bold">HOW SHOULD I USE CALCIPOTRIENE FOAM?</content></td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule" colspan="2"><list listType="unordered" styleCode="Disc"><item>Use calcipotriene foam exactly as your healthcare provider tells you to use it.

><tr><td styleCode="Lrule Rrule" colspan="2"><content styleCode="bold">HOW SHOULD I USE CALCIPOTRIENE FOAM?</content></td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule" colspan="2"><list listType="unordered" styleCode="Disc"><item>Use calcipotriene foam exactly as your healthcare provider tells you to use it. See the detailed &quot;<linkHtml href="#IFU">Instructions for Use</linkHtml>&quot; at the end of this leaflet for directions about how to apply calcipotriene foam the right way.</item><item>Calcipotriene foam is usually applied to the affected skin areas 2 times each day.</item><item>For your scalp, apply calcipotriene foam when your hair is dry.</item><item>Talk with your healthcare provider if your skin does not improve after 8 weeks of treatment with calcipotriene foam.</item><item>Wash your hands after applying calcipotriene foam unless you are using the medicine to treat your hands.</item></list></td></tr><tr><td styleCode="Lrule Rrule" colspan="2"><content styleCode="bold">WHAT SHOULD I AVOID WHILE USING CALCIPOTRIENE FOAM?</content></td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule" colspan="2"><list listType="unordered" styleCode="Disc"><item><content styleCode="bold">Calcipotriene foam is flammable</content>. Avoid fire, flame, and smoking during and right after you apply calcipotriene foam.</item><item>Avoid getting calcipotriene foam on your face or in or near your eyes. If calcipotriene foam gets on your face or in your eyes, rinse well with water.</item></list></td></tr><tr><td styleCode="Lrule Rrule" colspan="2"><content styleCode="bold">WHAT ARE THE POSSIBLE SIDE EFFECTS OF CALCIPOTRIENE FOAM? Calcipotriene foam may cause serious side effects, including:</content></td></tr><tr><td styleCode="Lrule Rrule" colspan="2"><list listType="unordered" styleCode="Disc"><item><content styleCode="bold">Too much calcium in your blood.</content> Your healthcare provider may tell you to stop using calcipotriene foam until your calcium levels become normal.</item></list></td></tr><tr><td styleCode="Lrule Rrule" colspan="2"><content styleCode="bold">The most common side effects of Calcipotriene foam</content> include redness and pain of the treated skin areas.</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule" colspan="2">These are not all the possible side effects of calcipotriene foam. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. You may also report side effects to Mayne Pharma at 1-844-825-8500.</td></tr><tr><td styleCode="Lrule Rrule" colspan="2"><content styleCode="bold">HOW SHOULD I STORE CALCIPOTRIENE FOAM?</content></td></tr><tr><td styleCode="Lrule Rrule" colspan="2"><list listType="unordered" styleCode="Disc"><item>Store calcipotriene foam at room temperature, between 68&#xB0;F to 77&#xB0;F (20C&#xB0; to 25&#xB0;C).</item><item>Do not store calcipotriene foam in the refrigerator or freezer.</item><item>Do not expose calcipotriene foam to heat or store at temperatures above 120&#xB0;F (49&#xB0;C).</item><item>Do not puncture or burn the calcipotriene foam can.</item></list></td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule" colspan="2"><content styleCode="bold">Keep calcipotriene foam and all medicines out of the reach of children.</content></td></tr><tr><td styleCode="Lrule Rrule" colspan="2"><content styleCode="bold">GENERAL INFORMATION ABOUT THE SAFE AND EFFECTIVE USE OF CALCIPOTRIENE FOAM.</content></td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule" colspan="2">Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use calcipotriene foam for a condition for which it was not prescribed.

UT THE SAFE AND EFFECTIVE USE OF CALCIPOTRIENE FOAM.</content></td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule" colspan="2">Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use calcipotriene foam for a condition for which it was not prescribed. Do not give calcipotriene foam to other people even if they have the same symptoms you have. It may harm them. You can ask your healthcare provider or pharmacist for information about calcipotriene foam that is written for health professionals.</td></tr><tr><td styleCode="Lrule Rrule" colspan="2"><content styleCode="bold">WHAT ARE THE INGREDIENTS IN CALCIPOTRIENE FOAM?</content></td></tr><tr><td styleCode="Lrule Rrule" colspan="2"><content styleCode="bold">Active ingredient:</content> calcipotriene</td></tr><tr><td styleCode="Lrule Rrule" colspan="2"><content styleCode="bold">Inactive ingredients:</content> cetyl alcohol, dibasic sodium phosphate, dl-&#x3B1;-tocopherol, edetate disodium, isopropyl myristate, light mineral oil, polyoxyl 20 cetostearyl ether, propylene glycol, purified water, stearyl alcohol, and white petrolatum. The foam is dispensed from an aluminum can pressurized with a hydrocarbon (propane/n-butane/isobutane) propellant.</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule" colspan="2">Distributed by: <content styleCode="bold">Mayne Pharma</content> Raleigh, NC 27609</td></tr></tbody></table>

Instructions for Use Calcipotriene (KAL-si-poe-TYRE-een)Foam, 0.005% Read this Instructions for Use before you start using calcipotriene foam and each time you get a refill. There may be new information. This information does not take the place of talking with your healthcare provider about your medical condition or treatment. Important Information: Calcipotriene foam is for use on the skin only (topical use). Do not use calcipotriene foam in your mouth, eyes, or vagina. Avoid getting calcipotriene foam on your face or in your eyes. If you accidentally get calcipotriene foam on your face or in your eyes, rinse well with water. How to apply calcipotriene foam to your body: Follow your healthcare providers instructions on how much calcipotriene foam to use and where to use it. Wash your hands after applying calcipotriene foam unless you are treating areas on your hands. Step 1. Before applying calcipotriene foam for the first time, break the tiny plastic piece at the base of the can's rim by gently pushing back (away from the piece) on the nozzle. See Figure A . Figure A Step 2: Shake the can of calcipotriene foam before use. See Figure B . Figure B Step 3: Turn the can of calcipotriene foam upside down and press the nozzle. See Figure C . Figure C Step 4. Dispense a small amount of calcipotriene foam into the palm of your hand. See Figure D . Figure D Step 5. Use enough calcipotriene foam to cover the affected area with a thin layer. Gently rub the foam into the affected area until it disappears into the skin. See Figures E and F Figure E Figure F How to apply calcipotriene foam to your scalp: Step 6 . Apply calcipotriene foam to your scalp when your hair is dry. Part your hair and apply directly on the affected area. See Figure G . Wash your hands after applying calcipotriene foam. Figure G This Instructions for Use has been approved by the U.S. Food and Drug Administration. Distributed by: Mayne Pharma , Raleigh, NC 27609 Revised: 04/2024 Figure A Figure B Figure C Figure D Figure E Figure F Figure G

DESCRIPTION Calcipotriene Ointment USP, 0.005% contains the compound calcipotriene, USP a synthetic vitamin D 3 derivative for topical dermatological use. Chemically, Calcipotriene, USP is 24-cyclopropyl-(1α,3β,5Z,7E,22E,24S)-9,10-Secochola-5,7,10(19),22-tetraene-1,3,24-trioI; with the empirical formula C 27 H 40 O 3 , a molecular weight of 412.62, and the following structural formula: Calcipotriene, USP is a white or almost white crystalline powder. Calcipotriene Ointment USP, 0.005% contains calcipotriene, USP 50 mcg/g in an ointment base of disodium phosphate dihydrate, edetate disodium, mineral oil, white petrolatum, propylene glycol, dl-alpha-tocopherol , steareth-2 and purified water. structure

CLINICAL PHARMACOLOGY In humans, the natural supply of vitamin D depends mainly on exposure to the ultraviolet rays of the sun for conversion of 7-dehydrocholesterol to vitamin D 3 (cholecalciferol) in the skin. Calcipotriene is a synthetic analog of vitamin D 3 . Clinical studies with radiolabelled calcipotriene ointment, USP indicate that approximately 6% (± 3%, SD) of the applied dose of calcipotriene is absorbed systemically when the ointment is applied topically to psoriasis plaques or 5% (± 2.6%, SD) when applied to normal skin, and much of the absorbed active is converted to inactive metabolites within 24 hours of application. Vitamin D and its metabolites are transported in the blood, bound to specific plasma proteins. The active form of the vitamin, 1,25-dihydroxy vitamin D 3 (calcitriol), is known to be recycled via the liver and excreted in the bile. Calcipotriene metabolism following systemic uptake is rapid, and occurs via a similar pathway to the natural hormone. The primary metabolites are much less potent than the parent compound. There is evidence that maternal 1,25-dihydroxy vitamin D 3 (calcitriol) may enter the fetal circulation, but it is not known whether it is excreted in human milk. The systemic disposition of calcipotriene is expected to be similar to that of the naturally occurring vitamin.

CLINICAL STUDIES Adequate and well-controlled trials of patients treated with calcipotriene ointment USP, 0.005% have demonstrated improvement usually beginning after 2 weeks of therapy. This improvement continued in patients using calcipotriene once daily and twice daily. After 8 weeks of once daily calcipotriene, 56.7% of patients showed at least marked improvements (6.4% showed complete clearing). After 8 weeks of twice daily calcipotriene, 70% of patients showed at least marked improvement (11.3% showed complete clearing). Subtracting percentages of patients using placebo (vehicle only) from percentages of patients using calcipotriene who had at least marked improvements after 8 weeks yields 39.9% for once daily and 49.6% for twice daily. This adjustment for placebo effect indicates that what might appear to be differences between once and twice daily use may reflect differences in the studies independent from the frequency of dosing. Although there was a numerical difference in comparison across studies, twice daily dosing has not been shown to be superior in efficacy to once daily dosing. Over 400 patients have been treated in open label clinical studies of calcipotriene for periods of up to one year. In half of these studies, patients who previously had not responded well to calcipotriene were excluded. The adverse reaction in these extended studies included skin irritation in approximately 25% of patients and worsening of psoriasis in approximately 10% of patients. In one of these open label studies, half of the patients no longer required calcipotriene by 16 weeks of treatment, because of satisfactory therapeutic results.

INDICATIONS AND USAGE Calcipotriene ointment USP, 0.005%, is indicated for the treatment of plaque psoriasis in adults. The safety and effectiveness of topical calcipotriene in dermatoses other than psoriasis have not been established.

CONTRAINDICATIONS Calcipotriene is contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation. It should not be used by patients with demonstrated hypercalcemia or evidence of vitamin D toxicity. Calcipotriene should not be used on the face.

PRECAUTIONS General Use of calcipotriene may cause irritation of lesions and surrounding uninvolved skin. If irritation develops, calcipotriene should be discontinued. For external use only. Keep out of the reach of children. Always wash hands thoroughly after use. Reversible elevation of serum calcium has occurred with use of calcipotriene. If elevation in serum calcium outside the normal range should occur, discontinue treatment until normal calcium levels are restored. Information for Patients Patients using calcipotriene should receive the following information and instructions: 1. This medication is to be used as directed by the physician. It is for external use only. Avoid contact with the face or eyes. As with any topical medication, patients should wash their hands after application. 2. This medication should not be used for any disorder other than that for which it was prescribed. 3. Patients should report to their physician any signs of local adverse reactions. 4. Patients that apply calcipotriene to exposed portions of the body should avoid excessive exposure to either natural or artificial sunlight. (including tanning booths, sun lamps, etc.) Carcinogenesis, Mutagenesis, Impairment of Fertility When calcipotriene was applied topically to mice for up to 24 months at dosages of 3, 10 and 30 mcg/kg/day (corresponding to 9, 30 and 90 mcg/m 2 /day), no significant changes in tumor incidence were observed when compared to control. In a study in which albino hairless mice were exposed to both UVR and topically applied calcipotriene, a reduction in the time required for UVR to induce the formation of skin tumors was observed (statistically significant in males only), suggesting that calcipotriene may enhance the effect of UVR to induce skin tumors. Patients that apply calcipotriene to exposed portions of the body should avoid excessive exposure to either natural or artificial sunlight (including tanning booths, sun lamps, etc.). Physicians may wish to avoid use of phototherapy in patients that use calcipotriene ointment USP, 0.005%. Calcipotriene did not elicit any mutagenic effects in an Ames mutagenicity assay, a mouse lymphoma TK locus assay, a human lymphocyte chromosome aberration assay, or in a micronucleus assay conducted in mice. Studies in rats at doses up to 54 mcg/kg/day (324 mcg/m 2 /day) of calcipotriene indicated no impairment of fertility or general reproductive performance. Pregnancy Teratogenic Effects Studies of teratogenicity were done by the oral route where bioavailability is expected to be approximately 40 to 60% of the administered dose. In rabbits, increased maternal and fetal toxicity were noted at a dosage 12 mcg/kg/day (132 mcg/m 2 /day); a dosage of 36 mcg/kg/day (396 mcg/m 2 /day) resulted in a significant increase in the incidence of incomplete ossification of the pubic bones and forelimb phalanges of fetuses. In a rat study, a dosage of 54 mcg/kg/day (318 mcg/m 2 /day) resulted in a significantly increased incidence of skeletal abnormalities (enlarged fontanelles and extra ribs). The enlarged fontanelles are most likely due to calcipotriene's effect upon calcium metabolism. The estimated maternal and fetal no-effect exposure levels in the rat (43.2 mcg/m 2 /day) and rabbit (17.6 mcg/m 2 /day) studies are approximately equal to the expected human systemic exposure level (18.5 mcg/m 2 /day) from dermal application. There are no adequate and well-controlled studies in pregnant women.

bolism. The estimated maternal and fetal no-effect exposure levels in the rat (43.2 mcg/m 2 /day) and rabbit (17.6 mcg/m 2 /day) studies are approximately equal to the expected human systemic exposure level (18.5 mcg/m 2 /day) from dermal application. There are no adequate and well-controlled studies in pregnant women. Therefore, calcipotriene ointment should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Nursing Mothers It is not known whether calcipotriene is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when calcipotriene ointment, 0.005% is administered to a nursing woman. Pediatric Use Safety and effectiveness of calcipotriene in pediatric patients have not been established. Because of a higher ratio of skin surface area to body mass, pediatric patients are at greater risk than adults of systemic adverse effects when they are treated with topical medication. Geriatric Use Of the total number of patients in clinical studies of calcipotriene ointment, USP approximately 12% were 65 or older, while approximately 4% were 75 and over. The results of an analysis of severity of skin-related adverse events showed a statistically significant difference for subjects over 65 years (more severe) compared to those under 65 years (less severe).

General Use of calcipotriene may cause irritation of lesions and surrounding uninvolved skin. If irritation develops, calcipotriene should be discontinued. For external use only. Keep out of the reach of children. Always wash hands thoroughly after use. Reversible elevation of serum calcium has occurred with use of calcipotriene. If elevation in serum calcium outside the normal range should occur, discontinue treatment until normal calcium levels are restored.

Information for Patients Patients using calcipotriene should receive the following information and instructions: 1. This medication is to be used as directed by the physician. It is for external use only. Avoid contact with the face or eyes. As with any topical medication, patients should wash their hands after application. 2. This medication should not be used for any disorder other than that for which it was prescribed. 3. Patients should report to their physician any signs of local adverse reactions. 4. Patients that apply calcipotriene to exposed portions of the body should avoid excessive exposure to either natural or artificial sunlight. (including tanning booths, sun lamps, etc.)

Carcinogenesis, Mutagenesis, Impairment of Fertility When calcipotriene was applied topically to mice for up to 24 months at dosages of 3, 10 and 30 mcg/kg/day (corresponding to 9, 30 and 90 mcg/m 2 /day), no significant changes in tumor incidence were observed when compared to control. In a study in which albino hairless mice were exposed to both UVR and topically applied calcipotriene, a reduction in the time required for UVR to induce the formation of skin tumors was observed (statistically significant in males only), suggesting that calcipotriene may enhance the effect of UVR to induce skin tumors. Patients that apply calcipotriene to exposed portions of the body should avoid excessive exposure to either natural or artificial sunlight (including tanning booths, sun lamps, etc.). Physicians may wish to avoid use of phototherapy in patients that use calcipotriene ointment USP, 0.005%. Calcipotriene did not elicit any mutagenic effects in an Ames mutagenicity assay, a mouse lymphoma TK locus assay, a human lymphocyte chromosome aberration assay, or in a micronucleus assay conducted in mice. Studies in rats at doses up to 54 mcg/kg/day (324 mcg/m 2 /day) of calcipotriene indicated no impairment of fertility or general reproductive performance.

Pregnancy Teratogenic Effects Studies of teratogenicity were done by the oral route where bioavailability is expected to be approximately 40 to 60% of the administered dose. In rabbits, increased maternal and fetal toxicity were noted at a dosage 12 mcg/kg/day (132 mcg/m 2 /day); a dosage of 36 mcg/kg/day (396 mcg/m 2 /day) resulted in a significant increase in the incidence of incomplete ossification of the pubic bones and forelimb phalanges of fetuses. In a rat study, a dosage of 54 mcg/kg/day (318 mcg/m 2 /day) resulted in a significantly increased incidence of skeletal abnormalities (enlarged fontanelles and extra ribs). The enlarged fontanelles are most likely due to calcipotriene's effect upon calcium metabolism. The estimated maternal and fetal no-effect exposure levels in the rat (43.2 mcg/m 2 /day) and rabbit (17.6 mcg/m 2 /day) studies are approximately equal to the expected human systemic exposure level (18.5 mcg/m 2 /day) from dermal application. There are no adequate and well-controlled studies in pregnant women. Therefore, calcipotriene ointment should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Teratogenic Effects Studies of teratogenicity were done by the oral route where bioavailability is expected to be approximately 40 to 60% of the administered dose. In rabbits, increased maternal and fetal toxicity were noted at a dosage 12 mcg/kg/day (132 mcg/m 2 /day); a dosage of 36 mcg/kg/day (396 mcg/m 2 /day) resulted in a significant increase in the incidence of incomplete ossification of the pubic bones and forelimb phalanges of fetuses. In a rat study, a dosage of 54 mcg/kg/day (318 mcg/m 2 /day) resulted in a significantly increased incidence of skeletal abnormalities (enlarged fontanelles and extra ribs). The enlarged fontanelles are most likely due to calcipotriene's effect upon calcium metabolism. The estimated maternal and fetal no-effect exposure levels in the rat (43.2 mcg/m 2 /day) and rabbit (17.6 mcg/m 2 /day) studies are approximately equal to the expected human systemic exposure level (18.5 mcg/m 2 /day) from dermal application. There are no adequate and well-controlled studies in pregnant women. Therefore, calcipotriene ointment should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Nursing Mothers It is not known whether calcipotriene is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when calcipotriene ointment, 0.005% is administered to a nursing woman.

Pediatric Use Safety and effectiveness of calcipotriene in pediatric patients have not been established. Because of a higher ratio of skin surface area to body mass, pediatric patients are at greater risk than adults of systemic adverse effects when they are treated with topical medication.

Geriatric Use Of the total number of patients in clinical studies of calcipotriene ointment, USP approximately 12% were 65 or older, while approximately 4% were 75 and over. The results of an analysis of severity of skin-related adverse events showed a statistically significant difference for subjects over 65 years (more severe) compared to those under 65 years (less severe).

ADVERSE REACTIONS Clinical Trials Experience In controlled clinical trials, the most frequent adverse reactions reported for calcipotriene were burning, itching and skin irritation, which occurred in approximately 10 to 15% of patients. Erythema, dry skin, peeling, rash, dermatitis, worsening of psoriasis including development of facial/scalp psoriasis were reported in 1 to 10% of patients. Other experiences reported in less than 1% of patients included skin atrophy, hyperpigmentation, hypercalcemia, and folliculitis. Once daily dosing has not been shown to be superior in safety to twice daily dosing. Postmarketing Experience The following adverse reactions have been identified during post approval use of Dovonex Ointment. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Renal and urinary disorders: hypercalciuria Skin and subcutaneous tissue disorders: application site edema, application site pain, contact dermatitis (including allergic contact dermatitis), depigmentation, hypopigmentation, photosensitivity, rash (including erythematous, maculo-papular, and pustular), and urticaria.

OVERDOSAGE Topically applied calcipotriene can be absorbed in sufficient amounts to produce systemic effects. Elevated serum calcium has been observed with excessive use of calcipotriene ointment USP, 0.005%.

STORAGE Store at controlled room temperature 15°C to 25°C (59°F to 77°F). Do not freeze. Distributed by: Glenmark Pharmaceuticals Inc., USA Elmwood Park, NJ 07407 Questions? 1 (888)721-7115 www.glenmarkpharma-us.com November 2025 glenmarklogo